Dese de alta para crear alertas sobre sus instrumentos,
eventos económicos y autores favoritos
Registrarse gratis ¿Ya tiene cuenta? Iniciar sesión
Cotizaciones
Todos los instrumentos
- Todos los instrumentos
- Índices
- Acciones
- ETFs
- Fondos
- Materias primas
- Divisas
- Cripto
- Bonos
- Certificados
Por favor, inténtelo con una nueva búsqueda
Descubre el poder de los datos premium: Hasta un 50% de descuento en InvestingPro QUIERO MI OFERTA
Ubs (lux) Equity Fund - Biotech (usd) Q-acc (0P0000XHD3)
Agregar/Eliminar del portafolio
Agregar a portafolio
328.670
+11.320
+3.57%
Tipo:
Fondo
Mercado:
Luxemburgo
Emisor:
UBS Fund Management (Luxembourg) S.A.
ISIN:
LU0400035332
Clase de activo:
Acciones
- Rating de Morningstar:
- Total de activos: 498.51M
UBS Lux Equity Fund - Biotech USD Q-acc
328.670
+11.320
+3.57%
Panorama 0P0000XHD3
En esta página encontrará un perfil detallado de Ubs (lux) Equity Fund - Biotech (usd) Q-acc. Conozca la gestión clave, los activos totales, la estrategia de inversión y la información de contacto de 0P0000XHD3, entre otros datos.
Información de contacto
Dirección
33A, avenue J.-F. Kennedy, L-1855 Luxembourg
Luxembourg, L-1855
Luxembourg
Luxembourg, L-1855
Luxembourg
Telefono
+352-441 0101
Ejecutivos
| Nombre | Título | Desde | Hasta |
|---|---|---|---|
| Sara Cotter | - | 2022 | Ahora |
| Matthew Konosky | - | 2017 | Ahora |
| Biografía | Matthew Konosky is the Lead Healthcare Portfolio Manager and a Senior Investment Analyst on UBS Asset Management's US Intrinsic Value Equity Team. In his portfolio manager role, Matthew is Lead Portfolio Manager for the Global Healthcare Lux Fund as well as Deputy Portfolio Manager for the Global Biotech Lux Fund. Analyst responsibilities include fundamental company and industry-level research and development of company earnings models for the global pharmaceuticals and health care services sectors. Prior to joining the firm in 2006, Matthew worked as health care services analyst at Sanford C. Bernstein in New York and as a senior consultant at Mars & Co. serving several Fortune 500 health care clients. Matthew has also served as a member of the MIT Educational Counsel since 1997. | ||
| Florian Töpfl | - | 2019 | 2023 |
| Nathalie Lötscher Petrus | - | 2006 | 2022 |
| Christian Suter | - | 2012 | 2019 |
| Biografía | Christian Suter is an Equity Specialist, based in Zurich. He works closely together with the equity investment teams of UBS Asset Management and is responsible for presenting equity strategies to clients, prospects and consultants, primarily focusing on our Swiss, Biotech and Healthcare strategies. Further Christian is the deputy portfolio manager for the Swiss High Dividend and Swiss Income strategies and acts as a member of the portfolio construction team for Swiss Equities. In addition Christian covers Swiss Small and Mid Cap Industrials as well as the Biotech sector as an analyst. In 2009, Christian joined UBS within the graduate training program for the second time, after he made his first experiences at UBS before University in UBS WM&SB and UBS Investment Bank. | ||
| André Leue | - | 2016 | 2017 |
| Biografía | André Leue is a Senior Investment Analyst. He is responsible for industry and company research, qualitative assessment and quantitative financial modelling within the Healthcare sector. André is Deputy Portfolio Manager for the UBS (Lux) Equity Fund – Biotech. André joined UBS Asset Management in February 2010. Prior to this he was head of the Healthcare team at DEKA Investment. As the Lead Portfolio Manager he was responsible for a Healthcare fund and a Biotech fund with combined assets under management of around USD 2bn. Other previous roles included senior financial analyst at Sal. Oppenheim Jr. & Cie and financial auditor at KPMG International. | ||
| Scott Wilkin | - | 2016 | 2016 |
| Biografía | Scott is the Head of the Global Intrinsic Value Equity team and co-PM for our Global equity portfolios. He is also Director of Research (DOR); responsible for managing the 13-member analyst team and driving research quality standards across the Global Intrinsic Value platform. In 2012, Scott was promoted to the position of DOR for the US Intrinsic Value equity team. In this role, Scott managed a team of six sector-based analysts and lead company and industry-level research. Scott was also the lead portfolio manager of the Intrinsic Value equity team's Global Healthcare and UBS Healthcare Long/Short strategies. Prior to being named DOR and portfolio manager, Scott was a Senior Investment Analyst and Sector Head for the health care analyst team. His responsibilities included fundamental company and industry-level research. | ||
| Sara Cotter | - | 2015 | 2016 |
| Angus Muirhead | - | 2012 | 2015 |
Escribe tus pensamientos respecto al Ubs (lux) Equity Fund - Biotech (usd) Q-acc
¿Estás seguro que quieres borrar este gráfico?
Eliminar Cancelar
¿Sustituir el gráfico adjunto por un nuevo gráfico?
Sustituir Cancelar
Guía para comentarios
Adjuntar un gráfico al comentario
Confirmar bloqueo
¿Está seguro de que desea bloquear a %USER_NAME%?
Al hacerlo, ni usted ni %USER_NAME% podrán ver las publicaciones del otro en Investing.com.
Se ha agregado correctamente a %USER_NAME% a su lista de usuarios bloqueados
Acaba de desbloquear a esta persona; tiene que esperar 48 horas para poder bloquearla de nuevo.
Denunciar este comentario
Díganos qué piensa de este comentario
Comentario denunciado
Gracias
Su denuncia será examinada por nuestros moderadores